PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas

Chih Ming Ho, Ming Chieh Lin, Shih Hung Huang, Chi Jung Huang, Hung Cheng Lai, Tsai Yen Chien, Shwu Fen Chang

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives: Loss of phosphatase and tensin homolog (PTEN) expression is common in ovarian clear cell adenocarcinomas (OCCA), but PTEN mutations are not frequently observed in OCCA. The mechanism of PTEN gene silencing in OCCA is still not clear. Materials and methods: Immunohistochemical analysis of PTEN expression was performed in 40 OCCA paraffin-embedded tissues. PTEN promoter methylation in 24 OCCA tissues and 5 OCCA cell lines was examined by methylation-specific PCR. Eighteen OCCA patients and 13 serous adenocarcinomas were analyzed for loss of heterozygosity (LOH) at 10q23 with five polymorphic markers. Results: Of the 40 OCCAs, 37.5% (15/40) had reduced PTEN immunoreactivity, LOH was found in 33% (6/18) of OCCAs, and 31% (4/13) of serous adenocarcinomas. In the 33% of OCCAs with LOH, only 33% (2/6) lost PTEN expression. PTEN promoter was unmethylated in 5 OCCA cell lines and 24 OCCA tissues detected by MSP-PCR. No significant correlation between PTEN expression and advanced stage disease or overall survival was found. Conclusion: Our results indicate that reduced PTEN expression was detected in more than one third of OCCA cases. Neither PTEN promoter methylation nor LOH at 10q23 locus is significantly related to PTEN inactivation and is not an adverse prognostic factor in OCCA.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalGynecologic Oncology
Volume112
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

Clear Cell Adenocarcinoma
Loss of Heterozygosity
Phosphoric Monoester Hydrolases
Methylation
Tensins
Adenocarcinoma
Cell Line
Polymerase Chain Reaction
Gene Silencing
Paraffin

Keywords

  • LOH
  • Ovarian clear cell carcinoma
  • Phosphatase and tensin homolog
  • Promoter methylation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. / Ho, Chih Ming; Lin, Ming Chieh; Huang, Shih Hung; Huang, Chi Jung; Lai, Hung Cheng; Chien, Tsai Yen; Chang, Shwu Fen.

In: Gynecologic Oncology, Vol. 112, No. 2, 02.2009, p. 307-313.

Research output: Contribution to journalArticle

Ho, Chih Ming ; Lin, Ming Chieh ; Huang, Shih Hung ; Huang, Chi Jung ; Lai, Hung Cheng ; Chien, Tsai Yen ; Chang, Shwu Fen. / PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. In: Gynecologic Oncology. 2009 ; Vol. 112, No. 2. pp. 307-313.
@article{747491bc57b94a42a36696b38747f1d1,
title = "PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas",
abstract = "Objectives: Loss of phosphatase and tensin homolog (PTEN) expression is common in ovarian clear cell adenocarcinomas (OCCA), but PTEN mutations are not frequently observed in OCCA. The mechanism of PTEN gene silencing in OCCA is still not clear. Materials and methods: Immunohistochemical analysis of PTEN expression was performed in 40 OCCA paraffin-embedded tissues. PTEN promoter methylation in 24 OCCA tissues and 5 OCCA cell lines was examined by methylation-specific PCR. Eighteen OCCA patients and 13 serous adenocarcinomas were analyzed for loss of heterozygosity (LOH) at 10q23 with five polymorphic markers. Results: Of the 40 OCCAs, 37.5{\%} (15/40) had reduced PTEN immunoreactivity, LOH was found in 33{\%} (6/18) of OCCAs, and 31{\%} (4/13) of serous adenocarcinomas. In the 33{\%} of OCCAs with LOH, only 33{\%} (2/6) lost PTEN expression. PTEN promoter was unmethylated in 5 OCCA cell lines and 24 OCCA tissues detected by MSP-PCR. No significant correlation between PTEN expression and advanced stage disease or overall survival was found. Conclusion: Our results indicate that reduced PTEN expression was detected in more than one third of OCCA cases. Neither PTEN promoter methylation nor LOH at 10q23 locus is significantly related to PTEN inactivation and is not an adverse prognostic factor in OCCA.",
keywords = "LOH, Ovarian clear cell carcinoma, Phosphatase and tensin homolog, Promoter methylation",
author = "Ho, {Chih Ming} and Lin, {Ming Chieh} and Huang, {Shih Hung} and Huang, {Chi Jung} and Lai, {Hung Cheng} and Chien, {Tsai Yen} and Chang, {Shwu Fen}",
year = "2009",
month = "2",
doi = "10.1016/j.ygyno.2008.09.040",
language = "English",
volume = "112",
pages = "307--313",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas

AU - Ho, Chih Ming

AU - Lin, Ming Chieh

AU - Huang, Shih Hung

AU - Huang, Chi Jung

AU - Lai, Hung Cheng

AU - Chien, Tsai Yen

AU - Chang, Shwu Fen

PY - 2009/2

Y1 - 2009/2

N2 - Objectives: Loss of phosphatase and tensin homolog (PTEN) expression is common in ovarian clear cell adenocarcinomas (OCCA), but PTEN mutations are not frequently observed in OCCA. The mechanism of PTEN gene silencing in OCCA is still not clear. Materials and methods: Immunohistochemical analysis of PTEN expression was performed in 40 OCCA paraffin-embedded tissues. PTEN promoter methylation in 24 OCCA tissues and 5 OCCA cell lines was examined by methylation-specific PCR. Eighteen OCCA patients and 13 serous adenocarcinomas were analyzed for loss of heterozygosity (LOH) at 10q23 with five polymorphic markers. Results: Of the 40 OCCAs, 37.5% (15/40) had reduced PTEN immunoreactivity, LOH was found in 33% (6/18) of OCCAs, and 31% (4/13) of serous adenocarcinomas. In the 33% of OCCAs with LOH, only 33% (2/6) lost PTEN expression. PTEN promoter was unmethylated in 5 OCCA cell lines and 24 OCCA tissues detected by MSP-PCR. No significant correlation between PTEN expression and advanced stage disease or overall survival was found. Conclusion: Our results indicate that reduced PTEN expression was detected in more than one third of OCCA cases. Neither PTEN promoter methylation nor LOH at 10q23 locus is significantly related to PTEN inactivation and is not an adverse prognostic factor in OCCA.

AB - Objectives: Loss of phosphatase and tensin homolog (PTEN) expression is common in ovarian clear cell adenocarcinomas (OCCA), but PTEN mutations are not frequently observed in OCCA. The mechanism of PTEN gene silencing in OCCA is still not clear. Materials and methods: Immunohistochemical analysis of PTEN expression was performed in 40 OCCA paraffin-embedded tissues. PTEN promoter methylation in 24 OCCA tissues and 5 OCCA cell lines was examined by methylation-specific PCR. Eighteen OCCA patients and 13 serous adenocarcinomas were analyzed for loss of heterozygosity (LOH) at 10q23 with five polymorphic markers. Results: Of the 40 OCCAs, 37.5% (15/40) had reduced PTEN immunoreactivity, LOH was found in 33% (6/18) of OCCAs, and 31% (4/13) of serous adenocarcinomas. In the 33% of OCCAs with LOH, only 33% (2/6) lost PTEN expression. PTEN promoter was unmethylated in 5 OCCA cell lines and 24 OCCA tissues detected by MSP-PCR. No significant correlation between PTEN expression and advanced stage disease or overall survival was found. Conclusion: Our results indicate that reduced PTEN expression was detected in more than one third of OCCA cases. Neither PTEN promoter methylation nor LOH at 10q23 locus is significantly related to PTEN inactivation and is not an adverse prognostic factor in OCCA.

KW - LOH

KW - Ovarian clear cell carcinoma

KW - Phosphatase and tensin homolog

KW - Promoter methylation

UR - http://www.scopus.com/inward/record.url?scp=58149503967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149503967&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.09.040

DO - 10.1016/j.ygyno.2008.09.040

M3 - Article

C2 - 19007975

AN - SCOPUS:58149503967

VL - 112

SP - 307

EP - 313

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -